Compare CLX & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLX | ILMN |
|---|---|---|
| Founded | 1913 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 20.5B |
| IPO Year | N/A | 2000 |
| Metric | CLX | ILMN |
|---|---|---|
| Price | $101.18 | $131.06 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 16 |
| Target Price | ★ $131.82 | $117.31 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 02-02-2026 | 02-05-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | ★ 121.91 | N/A |
| EPS | ★ 6.38 | 4.46 |
| Revenue | ★ $6,771,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | $2.24 |
| P/E Ratio | ★ $15.80 | $29.76 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $96.66 | $68.70 |
| 52 Week High | $164.22 | $153.06 |
| Indicator | CLX | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 51.81 |
| Support Level | $96.66 | $132.93 |
| Resistance Level | $104.86 | $135.95 |
| Average True Range (ATR) | 1.84 | 3.20 |
| MACD | 0.35 | -0.93 |
| Stochastic Oscillator | 54.62 | 16.88 |
Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.